|
RBM14 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.95627974825175E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.11419778853406E-11 |
| Normal-vs-Stage2 |
5.2758997171054E-10 |
| Normal-vs-Stage3 |
1.79967152291738E-12 |
| Normal-vs-Stage4 |
1.58270063721488E-11 |
| Stage1-vs-Stage2 |
4.757600E-01 |
| Stage1-vs-Stage3 |
1.918260E-02 |
| Stage1-vs-Stage4 |
2.036400E-01 |
| Stage2-vs-Stage3 |
3.564000E-01 |
| Stage2-vs-Stage4 |
6.872800E-01 |
| Stage3-vs-Stage4 |
6.479200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.8441918799067E-12 |
| Normal-vs-AfricanAmerican |
2.3970999999956E-05 |
| Normal-vs-Asian |
1.41779999962566E-07 |
| Caucasian-vs-AfricanAmerican |
2.677800E-01 |
| Caucasian-vs-Asian |
2.017700E-02 |
| AfricanAmerican-vs-Asian |
5.855000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.19113616140021E-12 |
| Normal-vs-Female |
1.24710242133119E-11 |
| Male-vs-Female |
1.177840E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.22329981886583E-11 |
| Normal-vs-Age(41-60Yrs) |
2.22044604925031E-16 |
| Normal-vs-Age(61-80Yrs) |
5.40678612992451E-14 |
| Normal-vs-Age(81-100Yrs) |
7.442500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.208800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.803850E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.750400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.027700E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.717000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.295800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.63769999994567E-06 |
| Classical-VS-Follicular |
1.082360E-02 |
| Classical-VS-Other |
4.267400E-01 |
| Classical-VS-Normal |
2.06100025934575E-10 |
| Tall-VS-Follicular |
2.025600E-01 |
| Tall-VS-Other |
5.032400E-01 |
| Tall-VS-Normal |
1.62947433324234E-12 |
| Follicular-VS-Other |
8.198600E-01 |
| Follicular-VS-Normal |
1.72406533494041E-12 |
| Other-VS-Normal |
1.616650E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.3611338418923E-12 |
| Normal-vs-N1 |
2.49256171258594E-12 |
| N0-vs-N1 |
1.738020E-01 |
|
|
